It's part of a larger effort to collaborate virtually. BIO will host a two-day virtual summit from March 24-25 to help biotech companies collaborate and share resources.
The summit, led by BIO President and CEO Jim Greenwood and Dr. George Scangos, President and CEO of Vir Biotechnology, will include a group of invited leaders from at least 45 biotech and pharmaceutical companies, global academic experts in virology and immunology, government officials and experts, and non-governmental organizations.
The next steps: Following the opening session, invited participants will join a number of closed breakout sessions focusing on diagnostics, therapeutics, and vaccines. The conversation will continue after the summit to maximize sharing of information, capabilities, and resources.
To see everything BIO and biopharmaceutical innovators are doing to respond to COVID-19 visit bio.org/coronavirus.
More Health Care News:
AP: Trump focuses attention on possible coronavirus treatments
“At a White House news conference, Trump and Food and Drug Administration Commissioner Dr. Stephen Hahn cited the malaria drug chloroquine, along with remdesivir, an experimental antiviral from Gilead Sciences, and possibly using plasma from survivors of COVID-19, the disease the new virus causes.”
STAT: With the coronavirus surging, Trump wants science to move far faster. It can’t
“The president’s remarks ran afoul of nearly every established FDA norm—prizing data and evidence over rhetoric, for instance, and avoiding promises, let alone those that can’t be kept. But they were also a sign of his long-running impatience with the realities of drug development—an impatience that is flaring at a time when the need for new medications seems more urgent than ever.”
The New York Times: Search for coronavirus vaccine becomes a global competition
“The United States, China and Europe are battling to be the first to find a cure, bringing a nationalist element to a worldwide crisis.”